Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

Kelly Anne Phillips, Roger L. Milne, Matti A. Rookus, Mary B. Daly, Antonis C. Antoniou, Susan Peock, Debra Frost, Douglas F. Easton, Steve Ellis, Michael L. Friedlander, Saundra S. Buys, Nadine Andrieu, Catherine Noguès, Dominique Stoppa-Lyonnet, Valérie Bonadona, Pascal Pujol, Sue Anne McLachlan, Esther M. John, Maartje J. Hooning, Caroline SeynaeveRob A.E.M. Tollenaar, David E. Goldgar, Mary Beth Terry, Trinidad Caldes, Prue C. Weideman, Irene L. Andrulis, Christian F. Singer, Kate Birch, Jacques Simard, Melissa C. Southey, Håkan L. Olsson, Anna Jakubowska, Edith Olah, Anne Marie Gerdes, Lenka Foretova, John L. Hopper

Research output: Contribution to journalArticleResearchpeer-review

128 Citations (Scopus)


Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers. Methods Analysis of pooled observational cohort data, self-reported at enrollment and at follow-up from the International BRCA1, and BRCA2 Carrier Cohort Study, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, and Breast Cancer Family Registry. Eligible women were BRCA1 and BRCA2 mutation carriers diagnosed with unilateral BC since 1970 and no other invasive cancer or tamoxifen use before first BC. Hazard ratios (HRs) for CBC associated with tamoxifen use were estimated using Cox regression, adjusting for year and age of diagnosis, country, and bilateral oophorectomy and censoring at contralateral mastectomy, death, or loss to follow-up. Results Of 1,583 BRCA1 and 881 BRCA2 mutation carriers, 383 (24%) and 454 (52%), respectively, took tamoxifen after first BC diagnosis. There were 520 CBCs over 20,104 person-years of observation. The adjusted HR estimates were 0.38 (95% CI, 0.27 to 0.55) and 0.33 (95% CI, 0.22 to 0.50) for BRCA1 and BRCA2 mutation carriers, respectively. After left truncating at recruitment to the cohort, adjusted HR estimates were 0.58 (95% CI, 0.29 to 1.13) and 0.48 (95% CI, 0.22 to 1.05) based on 657 BRCA1 and 426 BRCA2 mutation carriers with 100 CBCs over 4,392 person-years of prospective follow-up. HRs did not differ by estrogen receptor status of the first BC (missing for 56% of cases). Conclusion This study provides evidence that tamoxifen use is associated with a reduction in CBC risk for BRCA1 and BRCA2 mutation carriers. Further follow-up of these cohorts will provide increased statistical power for future prospective analyses.

Original languageEnglish
Pages (from-to)3091-3099
Number of pages9
JournalJournal of Clinical Oncology
Issue number25
Publication statusPublished - 1 Sep 2013
Externally publishedYes

Cite this